Case Studies – Absen
Trilogy Studios heralds the fusion of Absen’s Pixel Reality series and Brompton technology as a game-changer in the film and content creation arena. The studio benefits from over 145 million pixels spread across three stages, granting directors and cinematographers unparalleled flexibility and autonomy in their work. Unprecedented Collaborative Synergy The collaboration between Absen and…
Latest
Absen
Revolutionizing Fan Engagement at Orlando City Stadium
Orlando City and Orlando Pride have chosen Absen and Revel Media Group to elevate their fan engagement experience through innovative digital solutions. Instead of focusing on the hardware, these companies prioritize creating impactful fan experiences, tailoring their approach to engaging audiences with dynamic digital content. The Engagement Approach This partnership focuses on more than…
Latest
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…
What’s Next in Preclinical Cancer Immunotherapy Research?
As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
